The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1083
Gemtuzumab for Relapsed Acute Myeloid Leukemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Gemtuzumab for Relapsed Acute Myeloid Leukemia
Gemtuzumab ozogamicin, a monoclonal antibody bound to a cytotoxic antibiotic, has been approved by the FDA for treatment of patients with CD33-positive acute myeloid leukemia (AML) in first relapse who are more than 60 years old and may not be able...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Gemtuzumab for Relapsed Acute Myeloid Leukemia
Article code: 1083b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.